000181119 001__ 181119
000181119 005__ 20240229145640.0
000181119 0247_ $$2doi$$a10.3390/cancers14153708
000181119 0247_ $$2pmid$$apmid:35954372
000181119 0247_ $$2altmetric$$aaltmetric:134055812
000181119 037__ $$aDKFZ-2022-01788
000181119 041__ $$aEnglish
000181119 082__ $$a610
000181119 1001_ $$00000-0001-9332-4677$$aFranceschi, Enrico$$b0
000181119 245__ $$aAdult Medulloblastoma: Updates on Current Management and Future Perspectives.
000181119 260__ $$aBasel$$bMDPI$$c2022
000181119 3367_ $$2DRIVER$$aarticle
000181119 3367_ $$2DataCite$$aOutput Types/Journal article
000181119 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660554815_23718$$xReview Article
000181119 3367_ $$2BibTeX$$aARTICLE
000181119 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181119 3367_ $$00$$2EndNote$$aJournal Article
000181119 520__ $$aMedulloblastoma (MB) is a malignant embryonal tumor of the posterior fossa belonging to the family of primitive neuro-ectodermic tumors (PNET). MB generally occurs in pediatric age, but in 14-30% of cases, it affects the adults, mostly below the age of 40, with an incidence of 0.6 per million per year, representing about 0.4-1% of tumors of the nervous system in adults. Unlike pediatric MB, robust prospective trials are scarce for the post-puberal population, due to the low incidence of MB in adolescent and young adults. Thus, current MB treatments for older patients are largely extrapolated from the pediatric experience, but the transferability and applicability of these paradigms to adults remain an open question. Adult MB is distinct from MB in children from a molecular and clinical perspective. Here, we review the management of adult MB, reporting the recent published literature focusing on the effectiveness of upfront chemotherapy, the development of targeted therapies, and the potential role of a reduced dose of radiotherapy in treating this disease.
000181119 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000181119 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181119 650_7 $$2Other$$aSHH inhibitors
000181119 650_7 $$2Other$$aSHH pathway
000181119 650_7 $$2Other$$achemotherapy
000181119 650_7 $$2Other$$amedulloblastoma
000181119 650_7 $$2Other$$aneurosurgery
000181119 650_7 $$2Other$$aradiotherapy
000181119 650_7 $$2Other$$asonic hedgehog (SHH)
000181119 650_7 $$2Other$$asonidegib
000181119 650_7 $$2Other$$atargeted therapy
000181119 650_7 $$2Other$$avismodegib
000181119 7001_ $$aGiannini, Caterina$$b1
000181119 7001_ $$aFurtner, Julia$$b2
000181119 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b3$$udkfz
000181119 7001_ $$00000-0002-5035-2448$$aAsioli, Sofia$$b4
000181119 7001_ $$aGuzman, Raphael$$b5
000181119 7001_ $$aSeidel, Clemens$$b6
000181119 7001_ $$aGatto, Lidia$$b7
000181119 7001_ $$00000-0003-3894-5053$$aHau, Peter$$b8
000181119 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14153708$$gVol. 14, no. 15, p. 3708 -$$n15$$p3708$$tCancers$$v14$$x2072-6694$$y2022
000181119 909CO $$ooai:inrepo02.dkfz.de:181119$$pVDB
000181119 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181119 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000181119 9141_ $$y2022
000181119 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000181119 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000181119 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000181119 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000181119 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000181119 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000181119 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000181119 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000181119 980__ $$ajournal
000181119 980__ $$aVDB
000181119 980__ $$aI:(DE-He78)B062-20160331
000181119 980__ $$aI:(DE-He78)HD01-20160331
000181119 980__ $$aUNRESTRICTED